# RARE Ultragenyx Pharmaceutical Inc.

1. [Home](https://finlab.finance/en)
2. [U.S. Stocks](https://finlab.finance/en/stocks/us)
3. Ultragenyx Pharmaceutical Inc.(RARE)

Healthcare

17.22 USD Close 11/19

Since 2024-12-20 -61.1%

Close 11/19

* Open

  17.81

* High

  18.16

* Low

  17.06

* Prev close

  17.73

* Volume

  3.12M

* Amplitude

  6.20%

* Revenue YoY (TTM)

  +15.8%

52W 12.73 39.89

FinLab Studio

From Ultragenyx Pharmaceutical Inc. to every stock like it

AI finds several complementary traits of Ultragenyx Pharmaceutical Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

[Screen stocks like Ultragenyx Pharmaceutical Inc.](https://studio.finlab.finance/en/stocks/us/RARE)

## Is Ultragenyx Pharmaceutical Inc. a buy? Fundamentals and valuation first

As of 2026-11-19

Every dimension sits in the neutral range.

Valuation Neutral Free-cash-flow yield is Average.

TTM P/E -3.3 N/A

Price / book -4.7 N/A

Free-cash-flow yield (%) -25.2 22th percentile · Average

[US Stock Backtest in Python: Price-to-Book Ratio Strategy](https://finlab.finance/en/blog/us-stock-backtest-price-to-book-strategy)[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Quality Neutral ROE, TTM is Top, but Operating margin, TTM is Lagging.

ROE, TTM (%) 139.4 96th percentile · Top

Operating margin, TTM (%) -64.1 16th percentile · Lagging

FCF margin, TTM (%) -60.5 17th percentile · Lagging

[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Growth Neutral Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Average.

Revenue growth, TTM YoY (%) 15.8 69th percentile · Good

Diluted EPS growth, TTM YoY (%) -12.6 50th percentile · Average

Momentum Neutral All 2 indicators are Average.

60-day return (%) -34.9 23th percentile · Average

240-day return (%) -52.7 20th percentile · Average

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Lagging.

20-day dollar volume 64,029,386.0 83th percentile · Top

60-day annualized volatility (%) 108.0 83th percentile · Lagging

[Factor Investing Explained: 10 Classic Factors in US Stocks](https://finlab.finance/en/blog/us-factor-investing)

[Overview](https://finlab.finance/en/stocks/us/RARE#zone-position)[Peers](https://finlab.finance/en/stocks/us/RARE#zone-peers)[Signal backtests](https://finlab.finance/en/stocks/us/RARE#zone-evidence)

## Ultragenyx Pharmaceutical Inc. (RARE) peers and tracking

Watchlist

This page refreshes daily after the close. Add Ultragenyx Pharmaceutical Inc. to your watchlist to track signal changes on your next visit.

## Ultragenyx Pharmaceutical Inc. (RARE) quant signal backtests

### Market-wide momentum baseline

> Across 101,368 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.28%, a 58.5% positive-return rate, and +2.97 percentage points of average excess return versus the S\&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S\&P 500 (^GSPC).

More history: Signals not active now

### Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

### 52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

7 times historically; 60-day forward avg -5.0%, win rate 42.9%, beating the market by -9.4 pts on average.

### Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

19 times historically; 60-day forward avg -6.9%, win rate 31.6%, beating the market by -11.2 pts on average.

### Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

15 times historically; 60-day forward avg -3.6%, win rate 33.3%, beating the market by -8.4 pts on average.

### EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

[PEAD: Post-Earnings Announcement Drift Backtest](https://finlab.finance/en/blog/us-earnings-surprise-strategy)

10 times historically; 60-day forward avg +4.0%, win rate 50.0%, beating the market by +0.5 pts on average.

## Method and limits

* Returns use us\_price:adj\_close, adjusted for splits and dividends where available.
* Excess returns use world\_index:^GSPC as the S\&P 500 benchmark proxy.
* Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
* The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
* Snapshot-only tables such as analyst consensus, DCF, us\_ratios, and us\_key\_metrics are intentionally excluded from historical evidence.
* Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.

Further reading

Browse more quantitative analysis in [U.S. Stocks](https://finlab.finance/en/stocks/us). To turn these signals into backtestable rules, read the [Quantitative Trading Guide](https://finlab.finance/en/tools/quant-trading). Definitions of the Sharpe ratio, drawdown and other quant terms are in the [Quant Glossary](https://finlab.finance/en/glossary). Calculate this stock's risk-adjusted return with the [Sharpe Ratio Calculator](https://finlab.finance/en/tools/sharpe-ratio), and to automate the signals read the [Program Trading Guide](https://finlab.finance/en/tools/program-trading).

[Stock](https://finlab.finance/en/stocks/us/RARE)

Source: https://finlab.finance/en/stocks/us/RARE | Data dates: ../2026-11-19
